See how a next-generation low-volume, ready-to-drink bowel prep
can help support a successful colon cleanse for your patients1

See New Data

See how a next-generation low-volume,
ready-to-drink bowel prep can help support a
successful colon cleanse for your patients1

See New Data

A SUCCESSFUL PROCEDURE STARTS WITH THE PREP

TRIAL 1: Split-dose CLENPIQ has established successful cleansing of the entire colon2*

84% of patients achieved successful cleansing of the overall colon1,2*

The primary efficacy endpoint was the proportion of patients with successful colon cleansing, defined as “excellent” or “good”

90% of patients achieved successful cleansing of the ascending colon2*

A key secondary endpoint was the proportion of patients with successful cleansing of the ascending colon, defined as “excellent,” “good,” or “fair”

*Trial Design: The safety and efficacy of CLENPIQ have been established in clinical trials of another oral formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid. The efficacy of the split-dose regimen was evaluated for non-inferiority against a day-before comparator (2L PEG with electrolytes plus 2x5 mg bisacodyl tablets).1,2

Established safety profile1

The most common adverse reactions (≥1% of patients) were nausea (3%), headache (2%), and vomiting (1%)1*

*Abdominal bloating, distension, pain/cramping, and watery diarrhea not requiring an intervention were not collected.

NEW DATA

TRIAL 2: Split-dose CLENPIQ demonstrated proven efficacy in cleansing the entire colon3*

88% of patients achieved successful cleansing of the overall colon3*

The primary endpoint was the proportion of patients with successful colon cleansing, defined as “excellent” or “good”

Scoring was performed before washing and suctioning

*Trial Design: The safety and efficacy of CLENPIQ were evaluated in a randomized, multicenter, controlled, assessor-blinded trial. CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution (SPMC) was administered in a split-dose regimen against an oral powder (for reconstitution) (P/MC powder) and efficacy was evaluated using 2 different measurement scales.3 In this trial, CLENPIQ patients were instructed to drink at least five 8-ounce glasses of clear liquid within 5 hours of the first dose of CLENPIQ and at least four 8-ounce glasses of clear liquid within 4 hours of the second dose.3

TRIAL 2: Split-dose CLENPIQ demonstrated proven efficacy in cleansing all segments of the colon3*

94% of patients achieved successful cleansing of the ascending colon3*

Segmental colon

Assessed using the Boston Bowel Preparation scale3

Secondary efficacy endpoints were the proportion of patients with successful cleansing of the ascending, transverse, and descending colon, defined as a segmental score of “3” or “2”3

Scoring was performed after washing and suctioning3

Established safety profile3

The most common adverse reactions (≥2% of patients) were nausea (3%), headache (3%), and hypermagnesemia (2%); 1% of patients taking CLENPIQ experienced vomiting3

Hypermagnesemia levels were transient and not associated with any clinical significant sequelae. Eight of the 9 patients with hypermagnesemia returned to baseline within 24 to 48 hours. One patient returned to baseline by the day 7 follow-up visit.3

TRIAL 2: Patient compliance and tolerability were evaluated3†‡

Results from the Mayo Clinic Bowel Preparation Tolerability Questionnaire:

  • 99% of patients completed the majority of the CLENPIQ prep3§
  • 98% said they would be mostly or somewhat willing to take CLENPIQ again3
  • 90% felt that the tolerability of CLENPIQ was “easy” or “acceptable”3

†Trial Design: The efficacy and safety of CLENPIQ were evaluated in a randomized, multicenter, controlled, assessor-blinded trial. CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution (SPMC) was administered in a split-dose regimen against an oral powder (for reconstitution) (P/MC powder) and efficacy was evaluated using 2 different measurement scales.3

‡Subject compliance and tolerability with the bowel preparations were assessed by the validated Mayo Clinic Bowel Prep Tolerability Questionnaire, administered to patients on the day of their colonoscopies prior to the procedure.3

§Majority was defined as <25% of the bowel prep remaining after dosing.

Results from the questionnaire demonstrated that there was a high degree of tolerability and willingness to use CLENPIQ in the future3

Listen to the Experts:

Enhancing the patient colonoscopy journey How CLENPIQ can help support a successful colon cleanse

Can CLENPIQ help your patients prep for a successful procedure?

CLENPIQ is the next-generation low-volume, ready-to-drink bowel prep1

  • LOWEST VOLUME OF ACTIVE MEDICATION COMPARED WITH SUPREP®, PLENVU®, AND MoviPrep ®1,4-6*
  • NO MIXING OR DILUTING1
  • SUPPLIED IN TWO 5.4-OZ, READY-TO-DRINK BOTTLES1*

*Additional clear liquids are required for hydration.1,4-6

CLENPIQ provides easy-to-follow instructions for use

Click here to download the full instructions.

To open the CLENPIQ bottle: Place the bottle on a flat surface. Push down on the cap while twisting to the left (counterclockwise). Twist the cap until you see the white plastic ring under the cap is broken.

Drink, hydrate, repeat1

Clenpiq Split-Dose
Night Before
5:00 to 9:00 PM

At least five 8 oz cups (40 oz) of clear liquid over the next 5 hours

MORNING OF
5 hours before the procedure

At least three 8 oz cups (24 oz) of clear liquid. All clear liquid must be finished at least 2 hours before the procedure

See below for complete step-by-step instructions.

  • Encourage patients to hydrate on the day—before the procedure and consume only clear liquids.1,7

Download easy-to-follow instructions for your patients taking CLENPIQ split-dose
or day-before regimen as appropriate.

Step-By-Step Split-Dose Administration

Dose 1 – On the day before the colonoscopy:

  • Instruct patients to consume only clear liquids (no solid food or dairy) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy
  • Take the first dose (1 bottle) of CLENPIQ during the evening before the colonoscopy (eg, 5:00 to 9:00 pm)
  • Follow CLENPIQ by drinking at least five 8-ounce cups (cup provided) of clear liquids (40 ounces total) within 5 hours and before bed
  • If severe bloating, distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve

Dose 2 – Next morning on the day of the colonoscopy (start approximately 5 hours prior to colonoscopy):

  • Continue to consume only clear liquids (no solid food or dairy)
  • Take the second dose (the second bottle) of CLENPIQ
  • Following the CLENPIQ dose, drink at least three 8-ounce cups (cup provided) of clear liquids (24 ounces) at least 2 hours before the colonoscopy

Hydration is an important part of the prep

Patients can hydrate with any of the following clear liquids:

  • Water (plain or flavored)
  • Black coffee or tea (no milk, cream, soy, or nondairy creamer)
  • Clear broth or bouillon
  • Sports drinks (not red or purple)
  • Clear juices without pulp (such as apple juice or white grape juice)
  • Ginger ale and other sodas (not red or purple)
  • Plain Jell-O® (not red or purple)
  • Frozen juice bars (not red or purple)
CLENPIQ is also approved to be used in a day-before dosing regimen. Please refer to the Prescribing Information or the Patient Instructions for Use for day-before regimen instructions.

CLENPIQ savings support

Download the CLENPIQ coupon to help eligible patients save

The coupon can be used for commercially insured and cash-paying patients

Download to help patients save

Download the CLENPIQ coupon and your patients may be eligible to pay as little as $40 if they have commercial insurance, or to take $40 off the cash price. Terms and conditions apply.

Healthcare providers may download up to 10 cards
at a time.

*Plus applicable sales tax. Subject to eligibility and maximum benefit allowed.

References
  1. CLENPIQ® [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
  2. Rex DK, Katz PO, Bertiger G, et al. Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: the SEE CLEAR I study. Gastrointest Endosc. 2013;78(1):132-141.
  3. Hookey L, Bertiger G, Johnson II KL, Ayala J, Seifu Y, Brogadir SP. Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial [published online ahead of print May 19, 2019]. Ther Adv Gastroenterol. doi:10.1177/1756284819851510.
  4. SUPREP® Bowel Prep Kit [Prescribing Information]. Braintree, MA: Braintree Laboratories, Inc.
  5. PLENVU® [Prescribing Information]. Bridgewater, NJ: Salix Pharmaceuticals.
  6. MoviPrep® [Prescribing Information]. Bridgewater, NJ: Salix Pharmaceuticals.
  7. Lichtenstein GR, Cohen LB, Uribarri J. Review article: bowel preparation for colonoscopy—the importance of adequate hydration. Aliment Pharmacol Ther. 2007;26(5):633-641.

Indication and Important Safety Information

Indication

CLENPIQ oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Important Safety Information

  • CLENPIQ is contraindicated in the following conditions: patients with severe renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.
  • Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte abnormalities.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Use with caution in patients with impaired gag reflex as they may be at risk for regurgitation or aspiration during administration of CLENPIQ.
  • The safety of CLENPIQ has been established from adequate well controlled trials of another oral formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. The most common adverse reactions in those trials were nausea, headache, and vomiting.
  • CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.
Please see Full Prescribing Information.

Reference
1. CLENPIQ® [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.

Please see Important Safety Information and Full Prescribing Information

Indication and Important Safety Information

Indication

CLENPIQ oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Important Safety Information

  • CLENPIQ is contraindicated in the following conditions: patients with severe renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.
  • Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte abnormalities.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Use with caution in patients with impaired gag reflex as they may be at risk for regurgitation or aspiration during administration of CLENPIQ.
  • The safety of CLENPIQ has been established from adequate well controlled trials of another oral formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. The most common adverse reactions in those trials were nausea, headache, and vomiting.
  • CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.
Please see Full Prescribing Information.